Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both reduce death with potentially additive benefits when combined.
Key findingAnalysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both r
What the researchers found
Analysis of SGLT2 and GLP-1 drug impact on mortality in diabetic heart failure patients finds both reduce death with potentially additive benefits when combined.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
CARDIAB cohort study. Patients with T2D and established ASCVD. Mortality reduction with SGLT2 inhibitors and GLP-1 RAs demonstrated.
How the study worked
In publication.
Who was studied
Adults with type 2 diabetes and established atherosclerotic cardiovascular disease
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.
Cardiovascular diabetology, 24(1), 353
Citation
Arow, Ziad; Hornik-Lurie, Tzipi; Hilu, Ranin; Giladi, Ela; Arnson, Yoav; Vaknin-Assa, Hana; Assali, Abid; Pereg, David. (2025). SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.. Cardiovascular diabetology, 24(1), 353. https://doi.org/10.1186/s12933-025-02874-7